A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1887-1898

  Park, Ji Hye ^a   Ahn, Mee Young ^a   Kim, Tae Hyung ^a   Yoon, Sungpill ^b   Kang, Keon Wook ^c   Lee, Jaewon ^a   Moon, Hyung Ryong ^a   Jung, Jee H ^a   Chung, Hae Young ^a   Kim, Hyung Sik ^a  

^a Pusan National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Apoptosis; Autophagy; Breast cancer; HDAC inhibitor; Tamoxifen resistant

Indexed keywords

BECLIN 1; CASPASE; CELL PROTEIN; CYCLINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MHY 218; N1 HYDROXY N8 (4 PHENOXYPHENYL)OCTANEDIAMIDE; PROTEIN LC3 II; TAMOXIFEN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BREAST NEOPLASMS; CASPASES; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; G2 PHASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHENYL ETHERS; PIMELIC ACIDS; PROLIFERATING CELL NUCLEAR ANTIGEN; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867844169     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9752-z     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
2. Stewart DJ, Goel R, Cripps MC, Huan S, Yau J, Verma S (1997) Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study. Investig New Drugs 15(4):267-277
3. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Canc Res 54(6):1587-1595
4. Soni S, Lin BT, August A, Nicholson RI, Kirsch KH (2009) Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem 107(2):364-375
5. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Canc Inst 96(12):926-935
6. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Canc Res Treat 24(2):85-95
7. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Canc 11(4):643-658
8. Kim MR, Choi HS, Yang JW, Park BC, Kim JA, Kang KW (2009) Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression. Mol Canc Therapeut 8(8):2163-2171
9. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18(4):413-424
10. Ahn MY, Jung JH, Na YJ, Kim HS (2008) A natural histone deacetylase inhibitor, psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 108(1):27-33
11. Ahn MY, Lee J, Na YJ, Choi WS, Lee BM, Kang KW, Kim HS (2009) Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 179(2-3):169-177
12. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784
13. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Canc Res 13(16):4882-4890
14. Emanuele S, Lauricella M, Tesoriere G (2008) Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int J Oncol 33(4):637-646
15. Rosato R, Grant S (2004) Histone deacetylase inhibitors in clinical development. Expet Opin Investig Drugs 13(1):21-38
16. Margueron R, Duong V, Castet A, Cavaillès V (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68(16):1239-1246
17. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H (2005) Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Canc Biol Ther 4(9):956-960
18. Sharma D, Saxena NK, Davidson NE, Vertino PM (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Canc Res 66(12):6370-6378
19. Jeon HS, Ahn MY, Park JH, Kim TH, Chun P, Kim WH, Kim J, Moon HR, Jung JH, Kim HS (2010) Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. Int J Oncol 37(2):419-428
20. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19(21):5720-5728
21. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23(18):2495-2531
22. Papadopoulos T, Pfeifer U (1987) Protein turnover and cellular autophagy in growing and growth-inhibited 3T3 cells. Exp Cell Res 171(1):110-121
23. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Canc Cell 5(5):455-463
24. Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12(4):395-404
25. Minucci S, Pelicci P (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Canc 6(1):38-51
26. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26(9):1351-1356
27. Ozdaǧ H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C (2006) Differential expression of selected histone modifier genes in human solid cancers. BMC Genom 7:90-104
28. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Canc Res 92(12):1300-1304
29. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59(2):177-189
30. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(3):737-749
31. Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8(12):1505-1511
32. Kim JS, Lee S, Lee T, Lee YW, Trepel JB (2001) Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281(4):866-871
33. Im JY, Park H, Kang KW, Choi WS, Kim HS (2008) Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem Biol Interact 172(3):235-244
34. Dietrich CS, Greenberg VL, Desimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG (2009) Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecol Oncol 116(1):126-130
35. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27(13):4784-4795
36. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110(1):313-322
37. Yamamoto S, Tanaka K, Sakimura R, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S (2008) Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 28(3A):1585-1591
38. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132(1):27-42
39. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6):727-738
40. Oh M, Choi IK, Kwon HJ (2008) Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 369(4):1179-1183
41. Watanabe M, Adachi S, Matsubara H, Imai T, Yui Y, Mizushima Y, Hiraumi Y, Watanabe K, Kamitsuji Y, Toyokuni SY, Hosoi H, Sugimoto T, Toguchida J, Nakahata T (2009) Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation. Int J Canc 124(1):55-67
42. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Canc Res Treat 112(3):389-403